{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koeniger A"],"funding":["Julia Kirch","DFG","Gudrun Sander and Sebastian Mark for technical assistance","German Cancer Aid"],"pagination":["zcad007"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9900422"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["Transcriptional cancer subtypes which correlate with traits such as tumor growth, drug sensitivity or the chances of relapse and metastasis, have been described for several malignancies. The core regulatory circuits (CRCs) defining these subtypes are established by chromatin super enhancers (SEs) driving key transcription factors (TFs) specific for the particular cell state. In neuroblastoma (NB), one of the most frequent solid pediatric cancer entities, two major SE-directed molecular subtypes have been described: A more lineage-committed adrenergic (ADRN) and a mesenchymal (MES) subtype. Here, we found that a small isoxazole molecule (ISX), a frequently used pro-neural drug, reprogrammed SE activity and switched NB cells from an ADRN subtype towards a growth-retarded MES-like state. The "],"journal":["NAR cancer"],"pubmed_title":["Tumor-suppressive disruption of cancer subtype-associated super enhancer circuits by small molecule treatment."],"pmcid":["PMC9900422"],"funding_grant_id":["DFG-KFO325","70112599"],"pubmed_authors":["Polo P","Visekruna A","Gress TM","Koeniger A","Stiewe T","Lauth M","Adhikary T","Brichkina A","Nist A","Daude M","Diederich WE","Finkernagel F"],"additional_accession":[]},"is_claimable":false,"name":"Tumor-suppressive disruption of cancer subtype-associated super enhancer circuits by small molecule treatment.","description":"Transcriptional cancer subtypes which correlate with traits such as tumor growth, drug sensitivity or the chances of relapse and metastasis, have been described for several malignancies. The core regulatory circuits (CRCs) defining these subtypes are established by chromatin super enhancers (SEs) driving key transcription factors (TFs) specific for the particular cell state. In neuroblastoma (NB), one of the most frequent solid pediatric cancer entities, two major SE-directed molecular subtypes have been described: A more lineage-committed adrenergic (ADRN) and a mesenchymal (MES) subtype. Here, we found that a small isoxazole molecule (ISX), a frequently used pro-neural drug, reprogrammed SE activity and switched NB cells from an ADRN subtype towards a growth-retarded MES-like state. The ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-04-08T13:22:57.037Z","creation":"2025-02-19T00:12:14.621Z"},"accession":"S-EPMC9900422","cross_references":{"pubmed":["36755960"],"doi":["10.1093/narcan/zcad007"]}}